Voyager Therapeutics
Voyager Therapeutics is a biotechnology company focused on developing genetic medicines to treat neurological diseases, including Alzheimer’s, ALS, and Parkinson’s disease. The company utilizes its TRACER™ AAV capsid discovery platform to enhance delivery across the blood-brain barrier and collaborates with several major organizations.
Company Overview of Voyager Therapeutics
Voyager Therapeutics is a biotechnology company focused on creating transformative medicines for neurological diseases by leveraging human genetics. Headquartered at 75 Hayden Avenue, Lexington, MA 02421, the company specializes in the development of genetic therapies aimed at treating central nervous system disorders including Alzheimer's disease, ALS, and Parkinson’s disease. Voyager Therapeutics is committed to modifying and curing neurological illnesses through its innovative approach.
Voyager Therapeutics' Technology Platforms
Voyager Therapeutics employs state-of-the-art technology in its pursuit of neurogenetic medicines. One of the key technologies is the TRACER™ AAV capsid discovery platform, which has shown exceptional delivery capabilities across the blood-brain barrier. This platform plays a critical role in generating novel AAV capsids that enhance the company’s ability to deliver therapeutic agents to specific regions of the brain effectively.
Pipeline and Research at Voyager Therapeutics
Voyager Therapeutics is advancing a robust pipeline targeting several neurological disorders. The pipeline includes promising genetic medicines for conditions such as Alzheimer’s disease, ALS, and Parkinson’s disease. Projects include VY-TAU01, an anti-tau antibody for Alzheimer’s disease, and ongoing early research in Alzheimer’s gene therapy programs. Notable initiatives include a tau knock-down program and a vectorized anti-amyloid antibody program aimed at disease modification.
Voyager Therapeutics' Partnerships
Voyager Therapeutics collaborates with several leading organizations to further its gene therapy programs. Key partnerships include alliances with Neurocrine, Novartis, Alexion, and AstraZeneca, which help support the development and delivery of advanced gene therapies. These collaborations enable the company to leverage additional expertise and resources, accelerating progress towards effective neuromedicines.
Benefits for Voyager Therapeutics Employees
Voyager Therapeutics offers a comprehensive benefits package to its employees, emphasizing their well-being and work-life balance. The benefits include healthcare plans, unlimited vacation time, and several voluntary benefit programs. This approach aims to attract and retain top talent, fostering an environment that supports innovation and collaboration in the pursuit of advanced neurogenetic treatments.